Showing 691-700 of 8830 results for "".
Almirall/Allergan, LEO/Bayer Deals
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-almirall-allergan-leo-bayer-deals/18240/Leo Pharma has agreed to acquire Bayer's global prescription dermatology unit, and Almirall will acquire Allergan's US portfolio of medical dermatology drugs. When it comes to patient engagement, aesthetic practices often have the right mindset, but they may lack the skills or time necessary to execPsoriasis Comorbidities: Assessing Risks and the Role of Dermatologists
https://practicaldermatology.com/topics/psoriasis/psoriasis-comorbidities-assessing-risks-and-the-role-of-dermatologists-/18242/Ronald Prussick, MD discusses the most common comorbidities of psoriasis and the risks patients have for cardiovascular issues, depression, fatty liver disease, vitamin D deficiency, and more. He talks to host Nancy Samolitis, MD about the role dermatologists play in assessing and treating these risBiosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentJuvederm Approved for Lips, CoolMini Applicator Cleared
https://practicaldermatology.com/topics/psoriasis/juvederm-approved-for-lips-coolmini-applicator-cleared/18828/In this edition, a look at Allergan's Juvederm Voluma XC approval for lips an Zeltiq's CoolMini applicator for treatment of the sub mental area. Plus, there's new data for secukinumab in psoriatic arthritis (PSA) and Kathleen Sebelius has joined the Board of Directors of Dermira.Vitiligo Uncovered: Exploring the Latest Advances in Treatment and Care
https://practicaldermatology.com/youngmd-connect/ymdc-workshops/vitiligo-uncovered-exploring-latest-advances-treatment-and-care/29519/In this on-demand webinar, Dr. Domingues and Dr. Silverberg provide a comprehensive overview of vitiligo. This session covers the various types of vitiligo, essential patient evaluation techniques, and understanding disease progression. Learn about treatment strategies from both private practice andDermwireTV: Counterfeit Botox Cases Widen; New HS Treatment Approved in Europe
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-counterfeit-botox-cases-widen-new-hs-treatment-approved-europe/24419/In this episode of DermwireTV, the use of counterfeit Botox continues to widen; a first-of-its-kind drug is approved in Europe for hidradenitis suppurativa; and the PA Perspective series provides tips for training and onboarding in a new practice.An Updated, Holistic Approach to Managing Hyperpigmentation
https://practicaldermatology.com/topics/pigmentary-disorders/an-updated-holistic-approach-to-managing-hyperpigmentation/20102/As an early adopter of Cyspera, Suneel Chilukuri, MD has witnessed the evolution of the topical formulation. Cyspera Intensive System provides a three-step holistic approach to skincare that supports healthier, brighter skin within about four to six weeks.Advances in PsO: Targeting IL-23
https://practicaldermatology.com/conferences/aad-summer-2021/advances-in-pso-targeting-il-23/19974/George Han, MD, PhD reviews the latest data available on IL-23 inhibitors for the treatment of psoriasis. He discusses the specific benefits of guselkumab, tildrakizumab, and risankizumab and shares insights about how they fit into the overall psoriasis treatment arsenal.DermWireTV: Sanofi Genzyme & Regeneron Global AD Report; Hydroquinone; Pfizer NDA; VCS
https://practicaldermatology.com/topics/practice-management/dermwiretv-sanofi-genzyme-regeneron-global-ad-report-hydroquinone-pfizer-nda-vcs/19868/The “Improving Quality of Care in AD” report, commissioned and funded by Sanofi Genzyme & Regeneron and completed by KPMG, debuts at the annual meeting of the EADV. Changes to FDA regulations implemented as part of the CARES Act limit access to hydroquinone. This year’s Virtual Vegas Cosmetic SuBuyer Beware: CBD Products May Peddle False Hope Amid Corona Fears
https://practicaldermatology.com/series/dermatology-dispatches/buyer-beware-cbd-products-may-peddle-false-hope-amid-corona-fears/19775/Any claims that a medical cannabinoid-based product can kill COVID-19 are “absolutely unsubstantiated,” warns Adam Friedman, MD. There is no evidence that these products contain any antiviral properties, and patients should be advised against believing such claims.